Baker BROS. Advisors LP Acquires Shares of 1,023,130 Ventyx Biosciences, Inc. $VTYX

Baker BROS. Advisors LP bought a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,023,130 shares of the company’s stock, valued at approximately $3,182,000. Baker BROS. Advisors LP owned about 1.43% of Ventyx Biosciences at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in VTYX. Hudson Bay Capital Management LP bought a new position in shares of Ventyx Biosciences during the 2nd quarter worth $34,000. Engineers Gate Manager LP bought a new stake in Ventyx Biosciences in the 2nd quarter valued at about $42,000. Persistent Asset Partners Ltd bought a new stake in Ventyx Biosciences in the 3rd quarter valued at about $51,000. Jump Financial LLC purchased a new stake in Ventyx Biosciences during the second quarter valued at about $53,000. Finally, Jane Street Group LLC purchased a new stake in Ventyx Biosciences during the first quarter valued at about $56,000. 97.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of research reports. Wall Street Zen upgraded shares of Ventyx Biosciences to a “hold” rating in a research report on Saturday, March 7th. Piper Sandler cut shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price target on the stock. in a research note on Thursday, January 8th. Lifesci Capital reaffirmed a “market perform” rating and issued a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. UBS Group reiterated a “neutral” rating and issued a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Eight research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ventyx Biosciences presently has an average rating of “Reduce” and a consensus price target of $14.00.

Insider Activity at Ventyx Biosciences

In related news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John Nuss sold 12,675 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares in the company, valued at $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 14.49% of the stock is currently owned by insiders.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $14.00 on Friday. The business’s 50-day moving average price is $13.74 and its 200-day moving average price is $8.85. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $25.00. The stock has a market cap of $1.00 billion, a PE ratio of -9.33 and a beta of 1.26.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.